Seeking Alpha

Viiv Healthcare files fostemsavir application in Europe

|About: GlaxoSmithKline plc (GSK)|By: , SA News Editor

ViiV Healthcare has submitted a marketing application in Europe for fostemsavir, combined with other antiretrovirals, for the treatment of adults with multidrug-resistant HIV-1 infection.

The European Medicines Agency's advisory group CHMP will review the filing under accelerated assessment status.

Fostemsavir is a prodrug of temsavir, an HIV-1 attachment inhibitor that works by directly binding to the glycoprotein 120 subunit on the surface of the virus.

ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOY).